Search
Addition of obinutuzumab (GA101) or rituximab to chlorambucil improves outcomes for elderly patients with chronic lymphocytic leukemia (CLL) and co-existing medical conditions (comorbidities)
CLL is the most common leukemia in the western world. Many CLL patients are elderly and have comorbidities rendering them ineligible for aggressive standard treatments.
Read morePresidential Speakers
Promising crucial developments in the field of hematology, the speakers and presentation topics of the EHA2025 Presidential Session speakers are now available.
Friday, June 13, 2025 - Presidential Session I
Immunotherapy (TCR related)
Prof.
Abstract & Clinical Case Submission and Travel Grant
Abstract and clinical case procedureAbstract submission is closed
The official abstract submission closed on August 1, 2023 (23:59).
Program
Saturday, June 15, 2024 - Presidential Session I
Conducting multinational RCTs in pregnancy to improve maternal health in thrombosis: it CAN be done
Prof. Saskia Middeldorp, The Netherlands
Targeting the epigenome in lymphoma
Prof.
How to apply
The CRTH 2025 call for applications is now closed. Timelines
Application CRTH 2025
Deadline: September 24, 2024 (15:00 CEST)
Notification
November 2024
Questions: training@ehaweb. orgDownload the Signature letter template.